SUBSCRIBE
SUBSCRIBE
Pharm Country

Pozen, Inc. Migraine Drug Fails to Get Patent Extension

February 24, 2011 | 
1 min read

Reuters -- Pozen Inc said U.S. health regulators will not grant a pediatric exclusivity to its Treximet migraine drug, a decision that can open up generic competition for the drug.

MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Pictured: Man holding tablet computer with scienti
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Mother covering her face, experiencing depression symptoms
Drug Development
Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial
May 3, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Business
BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases
April 29, 2024
 · 
2 min read
 · 
Tyler Patchen